DENVER, Colo., Oct 9, 2023 (www.247marketnews.com)- Immunic, Inc. (NASDAQ: IMUX) reported, after yesterday’s market close, positive interim data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS). The 24-week data from the first half of patients shows improvements in biomarker NfL, consistent throughout the overall progressive multiple sclerosis population, as well as all subtypes, which Immunic believes shows biomarker evidence that vidofludimus calcium’s activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential.
Immunic is trading at $1.87, up $0.28 (+17.61%), up 5.81M premarket shares traded.
Its 52-week range is $1.11 to $11.76. Its next inflection points are $1.90 and $2.00, with the latter being a key resistance point that could unlock a run, but trading volume needs to strengthen.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.